News

Hims & Hers Stock Tumbles as Novo Nordisk Ends Its Wegovy Sales Deal. Can the Telehealth Giant Recover?
The stock's market-beating momentum has come crashing to a halt, following shocking allegations from one of the world's largest pharmaceutical companies.
Exclusive-New data show most US patients now stay on Wegovy, Zepbound after a year
By Chad Terhune LOS ANGELES (Reuters) -Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last ...
Novo Nordisk halts Wegovy sales on Hims & Hers, claiming "deceptive marketing" practices
Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the ...
Wegovy: The price, perks, and pitfalls of India’s new weight-loss craze
Wegovy, the ₹26K/month weight-loss jab, hits India with bold promises—from fat loss to heart health. But is this pharma fix a ...
Novo Nordisk launches weight-loss drug Wegovy in India to compete with Lilly's Mounjaro
Danish drugmaker Novo Nordisk on Tuesday launched its blockbuster weight-loss drug Wegovy in India, three months after Eli ...
Explained: Everything you need to know ahead of Wegovy's NZ arrival
The count-down's on for New Zealand chemist sales of weight-loss drug Wegovy. A pharmacist has told our newsroom the ...
Strict criteria Brits need to fit in order to be eligible for Wegovy from NHS
NICE says that in some exceptional circumstances the BMI requirements can drop down to 30, and people from some ethnic ...
New data show most patients now stay on Wegovy, Zepbound after a year
Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year ...